The preclinical tox issue (intense immune stimulation) have been found with ANA975, a toll-like receptor-7 (TLR-7) agonist. ANA598 is an oral nonnucleoside HCV polymerase inhibitor that binds to a unique site on the HCV NS5b enzyme and has a clean safety profile so far.